Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malmeström, C.
Right arrow Articles by Lycke, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malmeström, C.
Right arrow Articles by Lycke, J.
Related Collections
Right arrow Autoimmune diseases
Right arrow Multiple sclerosis
NEUROLOGY 2003;61:1720-1725
© 2003 American Academy of Neurology

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS

C. Malmeström, MD, S. Haghighi, MD, L. Rosengren, MD PhD, O. Andersen, MD PhD and J. Lycke, MD PhD

From the Institute of Clinical Neuroscience, Department of Neurology, Göteborg University, Sahlgrenska University Hospital, Sweden.

Address correspondence and reprint requests to Dr. J. Lycke, Institute of Clinical Neuroscience, Department of Neurology, Göteborg University, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden; e-mail: jan.lycke{at}neuro.gu.se

Objective: To determine if CNS-derived proteins present in the CSF of multiple sclerosis (MS) patients reflect different pathologic processes of MS and if these proteins could be useful as biologic markers of disease activity.

Methods: Concentrations of the neurofilament light protein (NFL), glial fibrillary acidic protein (GFAP), S100B, and the neuron-specific enolase protein (NSE) were determined in the CSF of 66 MS patients and 50 healthy control subjects with immunoassays.

Results: The mean levels of the NFL were increased during all stages of MS compared with controls (p < 0.001), peaking almost 10 times higher during acute relapses. The highest levels of GFAP were found during the secondary progressive course (p < 0.001) with a strong correlation with neurologic deficits (Expanded Disability Status Scale score, r = 0.73, p < 0.001). No increase of S100B or NSE protein was found in the CSF of MS patients compared with control subjects.

Conclusions: Increased level of NFL is a general feature of MS, indicating continuous axonal damage during the entire course of the disease with the most profound damage during acute relapses. GFAP may serve as a biomarker for disease progression, probably reflecting the increasing rate of astrogliosis.

Received March 31, 2003. Accepted in final form August 20, 2003.




This article has been cited by other articles:


Home page
 Mult SclerHome page
K. Rejdak, A. Petzold, Z. Stelmasiak, and G. Giovannoni
Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis
Multiple Sclerosis, January 1, 2008; 14(1): 59 - 66.
[Abstract] [PDF]

Home page
 NeurologyHome page
A Mellgren, R. W. Price, L. Hagberg, L. Rosengren, B. J. Brew, and M. Gisslen
Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection
Neurology, October 9, 2007; 69(15): 1536 - 1541.
[Abstract] [Full Text] [PDF]

Home page
 Vet Rec.Home page
Y. Toda, N. Matsuki, M. Shibuya, I. Fujioka, S. Tamahara, and K. Ono
Glial fibrillary acidic protein (GFAP) and anti-GFAP autoantibody in canine necrotising meningoencephalitis
Vet Rec., August 25, 2007; 161(8): 261 - 264.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A Petzold, M J Eikelenboom, G Keir, C H Polman, B M. Uitdehaag, E J Thompson, and G Giovannoni
The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers
Multiple Sclerosis, June 1, 2006; 12(3): 325 - 328.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J Brettschneider, A Petzold, A Junker, and H Tumani
Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis
Multiple Sclerosis, April 1, 2006; 12(2): 143 - 148.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Petzold, M J Eikelenboom, G Keir, D Grant, R H C Lazeron, C H Polman, B M J Uitdehaag, E J Thompson, and G Giovannoni
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study
J. Neurol. Neurosurg. Psychiatry, February 1, 2005; 76(2): 206 - 211.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
J. M. FRIEDBERG
Astrocytic Activation as Evidence for Brain Damage
Am J Psychiatry, January 1, 2005; 162(1): 195 - 196.
[Full Text] [PDF]

Home page
 Mult SclerHome page
R Ehling, A Lutterotti, J Wanschitz, M Khalil, C Gneiss, F Deisenhammer, M Reindl, and T Berger
Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis
Multiple Sclerosis, December 1, 2004; 10(6): 601 - 606.
[Abstract] [PDF]

Home page
 NeurologyHome page
J. R. Avasarala, J. N. Lycke, C. Malmestrom, S. Haghighi, L. Rosengren, and O. Andersen
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
Neurology, August 10, 2004; 63(3): 599 - 599.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
Jagannadha R Avasarala
Neurology Online, 3 Feb 2004 [Full text]
Reply to Avasarala
Jan N. Lycke, et al.
Neurology Online, 3 Feb 2004 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.